tbuckley/cabot-search huggingface dataset:
Nanoporous silicon delivery vectors for breast cancer imaging.
Authors: RE Serda, B Godin, J Bankson, P Decuzzi, M Ferrari
Journal: Cancer Research (2009)

Abstract Abstract #4003 Nano- and micro-sized delivery systems are emerging as powerful tools for the systemic delivery of therapeutic and imaging agents in different biomedical applications, from cancer to cardiovascular diseases. These delivery systems can be loaded with a multitude of drug molecules and contrast agents to simultaneously provide therapeutic and imaging capabilities. Following intravenous injection, these particles are transported by the blood stream into different vascular districts. We have recently introduced a multi-stage delivery system designed to overcome sequential biological barriers. The first stage, comprised of porous silicon microparticles, targets tumor-associated endothelium. Once arrested at the tumor site, second stage nanoparticles, carrying therapeutic and imaging agents are released into the tumor microenvironment by time-dependent degradation of the silicon vehicle. Free nanoparticles cross the endothelial barrier by the inherent leaky nature of the tumor vessel, a phenomenon known as enhanced permeation and retention. In this study, iron oxide nanoparticles serve as contrast agents for visualizing distribution in murine mammary tumors using magnetic resonance imaging.&amp;#x2028; The silicon microparticles are hemispherical in shape, a design that facilitates margination and interaction of particles with the endothelium. Loading of iron oxide nanoparticles into the silicon microparticles was accomplished by covalent attachment. The loaded particles were characterized by Prussian Blue quantitation of iron, as well as SEM and TEM analysis. Human breast cancer xenografts were established in nude mice by injection of 4T1 mouse mammary carcinoma cells into fatpads of Crl Foxnu nude mice. At day 15, mice were intraveneously administered either free iron oxide nanoparticles, or 1 x 108 silicon microparticles, non-loaded or loaded with iron oxide nanoparticles. Magnetic resonance imaging was carried out using a 7 Telsa magnetic resonance imager. Serial sagittal T2-weighted images revealed tumors with hypointense contrast for animals injected with free and multi-stage encapsulated iron oxide nanoparticles at both 3 and 5 hr. A separate quantitative study compared iron and silicon content in lungs, liver, spleen, kidney, and tumor by inductive coupled plasma atomic emission spectroscopy analysis of organs from 25 mice 5 hrs following tail vein injections of the following systems: 1) saline control, 2) silicon microparticles (Si), 3) iron oxide nanoparticles, and 4) iron oxide loaded silicon particles. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 4003.
Abstract P1-14-16: Young age: predicts poor response rate after neoadjuvant chemotherapy in endocrine-responsive breast cancer
Authors: MK Kim, D-Y Noh, W Han, H-G Moon, S-K Ahn, JS Kim, T Kim, JY Kim, JW Lee
Journal: Cancer Research (2012)

Abstract Background: Breast cancer rarely occurs in very young women(age&amp;lt;35years), its diagnosis and management could sometimes be difficult. Especially, the patients with positive hormone receptors have significantly lower overall and disease-free survival rates in very young age group than in the older age group. In the previous study, adjuvant tamoxifen therapy might provide less survival benefit when added to chemotherapy in very young breast cancer patients. This study was to compare the response to neoadjuvant chemotherapy for HR-positive breast cancer patients according to the age. Patients and Methods: A total of 551 consecutive patients were evaluated, received preoperative chemotherapy and referred to surgery at the Seoul National University Hospital from January 2001 to December 2010. The clinicopathologic factors and the response to neoadjuvant chemotherapy between the very young age group and the older age group were retrospectively compared. A pCR was defined as the absence of residual invasive carcinoma in the breast. Results: Among the 551 patients who received neoadjuvant chemotherapy, 297 patients revealed HR-positive. The median age of all patients was 42 (range, 24∼67)years and very young age group accounted for 17.2%(51/297). Of 297 patients, 262 (88.2%) received taxane-containing regimen pre-operatively, and there's no difference of chemotherapeutic regimen between two age groups. There were no differences noted between two age groups about clinicopathologic characteristics. The univariate and multivariate analysis of variables related to ORR(CR+PR vs SD+PD) to neoadjuvant chemotherapy showed that very young age at diagnosis was independent predictive factor for poor neoadjuvant chemotherapeutic response.(p = 0.043, OR = 0.528) And this tendency was observed more significantly in age under 30.(p = 0.001, OR = 0.147) Only thirteen patients(4.4%) achieved pCR, which is relatively lower rate, reflective poor chemotherapeutic response in HR-positive group, and there was no relations between pCR rate and the two age groups(p = 0.861) in this study. Taxane-containing regimen(p = 0.004) and Ki67 level(p = 0.005) were related to pCR statistically significantly. Breast conservation rate is not significantly different between two age groups.(age&amp;lt;35: age&amp;gt;35= 51.2% vs 41.3%, p = 0.150) Conclusions: The very young age group showed lower ORR(CR+PR) to neoadjuvant chemotherapy, although there was no significant difference in pCR rate between the two age groups in HR-positive breast cancer patients. We might have to consider and revalue the chemotherapeutic role as neoadjuvant therapy in very young age, HR-positive group, since they had lower survival rate than others. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-14-16.
Abstract 4643: Shedding light on the molecular basis of tumor dormancy using antiangiogenic nanomedicines
Authors: Galia Tiram, Ehud Segal, Gal Bachar, Roni Shreberk, Paula Ofek, Ronit Satchi-Fainaro
Journal: Cancer Research (2012)

Abstract Based on clinical necessity for improved anticancer drugs and the importance of understanding the mechanism underlying the angiogenic switch phenomenon, we designed a targeted drug delivery system for the treatment of bone-related angiogenesis-dependent malignances. Using multidisciplinary approaches involving novel chemistry and molecular imaging, we synthesized polymer-drug nano-conjugates of HPMA copolymer-alendronate bound to TNP-470 or paclitaxel designed to target the angiogenic switch of bone neoplasms such as osteosarcoma and bone metastases. Antitumor efficacy of the conjugates was evaluated in osteosarcoma- and breast cancer bone metastases-bearing mice revealing improved anti-angiogenic and antitumor activity with reduced toxicity compared with the free drugs. To obtain data regarding the pharmacokinetic profiles of the drugs, we developed a novel prodrug system that enables real-time monitoring of drug release by different fluorescence imaging modalities. To further analyze host-tumor interactions in response to treatment, we developed a model of tumor dormancy based on mCherry-infected human osteosarcoma cells that allows deep tissue signal penetration with an optical readout. This pair of tumor cells that originate from the same parental cell line, enable intravital non-invasive detection of early stages of cancer and evaluation of treatment efficacy with the nanoconjugate. The pair has similar growth rate in vitro. However, when inoculated into mice, Saos-2-E cells established a vascularized and palpable tumor within one month, while Saos-2-D cells remained avascular and non-palpable for a year until they spontaneously escape. Phenotypic and molecular (microRNA-based) differences between these two cell lines were evaluated by in vitro and in vivo methods, with emphasis on changes related to the angiogenesis process. Although slight differences between the Saos-2-D and Saos-2-E cells were shown in vitro, when inoculated in vivo Saos-2-E cells showed increased angiogenic potential compared with the Saos-2-D cells. Our nanoconjugate was able to regress fast growing-angiogenic human tumors to a dormant avascular phenotype. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4643. doi:1538-7445.AM2012-4643
Case 13-2014
Authors: Dimitrios P. Kontoyiannis, Mahan Mathur, Yi-Bin Chen, Paul C. Shellito, Julie Y. Tse
Journal: New England Journal of Medicine (2014)

A 41-year-old man with B-cell acute lymphoblastic leukemia underwent allogeneic peripheral-blood stem-cell transplantation; 12 days later, fever, abdominal pain, and peritoneal signs developed. Imaging showed acute retrocecal appendicitis and inflammation of the cecum.
European Cancer Center Links Basic and Clinical Science
Authors: C. Vanchieri
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article European Cancer Center Links Basic and Clinical Science Get access Cori Vanchieri Cori Vanchieri Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 17, 1 September 1993, Pages 1370–1371, https://doi.org/10.1093/jnci/85.17.1370 Published: 01 September 1993
YB-1 Mediates a Crosstalk between ERα and TGFβ Signaling in Breast Cancer Cells.
Authors: S. Popp, M. Stope, M. Buck, C. Joffroy, P. Fritz, C. Knabbe
Journal: Cancer Research (2009)

Abstract The multifunctional Y-box binding protein-1 (YB-1) belongs to the highly conserved family of cold shock proteins being involved in transcriptional/translational regulation, DNA repair as well as stress response. Additionally, it is highly expressed in many malignant tissues which seems to correlate with a high proliferation level, drug resistance and a poor prognosis in a variety of tumors including breast cancer.Using quantitative immunohistochemistry we now confirm the previously described negative prognostic impact of YB-1 on survival in a clinical study with tumor samples from 199 breast cancer patients (p=0.0146; median follow up 79 months).Treatment of the estrogen receptor α (ERα) positive human breast cancer cell line MCF-7 with antiestrogens (4-hydroxytamoxifen, faslodex) resulted in a time and dose dependent decrease of YB-1 expression on the RNA- as well as on the protein level. In contrast, antiestrogen treatment of the ERα negative cell line MDA-MB-231 does not have any effect indicating that the antiestrogen effect on YB-1 is mediated by ERα. We have already demonstrated that the action of all antiestrogens is at least partially mediated by transforming growth factor β (TGFβ) (e.g. Breast Cancer Res. Treat. 107: 15-24, 2008). Using TGFβ-responsive reporter gene assays we now show that overexpression of YB-1 in MCF-7 cells enhances the induction of p3TPlux activity by TGFβ suggesting a crosstalk between YB-1 and TGFβ signaling pathways. Moreover, YB-1 also increases the antiestrogen induction of the TGFβ2-mRNA level coming along with a YB-1 regulated enhancement of the antiestrogen effect on cell growth.Very recent findings of our group point towards a ligand-independent influence of ERα on TGFβ signaling (Breast Cancer Res. Treat., in press). Due to the antiestrogen regulation of YB-1 via ERα and its crosstalk with the TGFβ pathway, the potential role of YB-1 as a mediator of the interaction between ERα and TGFβ signaling was analyzed. Performing pull-down assays with recombinant GST-ERα and whole cell lysates of MCF-7 cells confirms a protein-protein interaction between YB-1 and ERα. The physiological relevance of this interaction could be demonstrated, as the TGFβ-induced p3TPlux activity is clearly modulated by both, YB-1 and ERα.In conclusion, we present evidence that YB-1 and TGFβ signaling are functionally linked in MCF-7 cells. Combined with the detection of a physical interaction between YB-1 and ERα, our findings shed new light on a potential role of YB-1 as a part of the mechanism responsible for switching TGFβ from its anti-proliferative role in early tumor stages to tumor promoting effects in late-stage disease, most likely via a YB-1 regulated shift of TGFβ-signaling to pro-invasive pathways. This would also explain why high levels of YB-1 correlate with a poor prognosis in breast cancer patients. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 4172.
THU0550 Complex Rehabilitation of Patients with Early Rheumatoid Arthritis: Results of 6-Month Program
Authors: E. Orlova, D. Karateev, E. Nasonov, A. Kochetkov
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Rehabilitation techniques give the people with rheumatoid arthritis (RA) the strategies necessary to manage their disease in addition to medical treatment [1, 2]. However, the efficiency of early rehabilitation of RA patients remains a controversial area in rheumatology. <h3>Objectives</h3> To evaluate the efficacy of complex rehabilitation program for patients with early RA within 6 months. <h3>Methods</h3> 60 patients with early RA (88,3% females, age of 18 to 63 years, disease duration of 2 to 18 months) were included. 34 study group patients underwent drug therapy and rehabilitation program (hospital stage (2 weeks): local air cryotherapy (–60°C, Criojet Air C600) for hand, knee or ankle joints for 15 min, 45-min therapeutic exercises under the supervision of a trainer, 45-min occupational therapy (joint protection strategies, use of assistive devices and adaptive equipment), 10 sessions, education program (4 daily 90-min studies) and outpatient stage (6 months): 45-min home exercises 3 times a week, orthoses (functional wrist and knee orthoses, individual orthopedic insoles)). 26 patients received only drug therapy (control). Tender and swollen joint count, erythrocyte sedimentation rate (ESR), joint pain on 100-mm VAS, DAS28, HAQ, RAPID3, hand grip strength, the average powers of knee extension and ankle flexion by the EN-TreeM movement analysis were evaluated at baseline, at 2 weeks and at 6 months. <h3>Results</h3> The rehabilitation reduced needs for nonsteroidal anti-inflammatory drugs by 32,3% (p&lt;0,05), enhanced adherence to joint protection strategies by 10,5 times (p&lt;0,01), orthosis wearing by 44,4–72,7% (p&lt;0,01), regular physical activity by 4,5 times (p&lt;0,01). 22 patients finished 6-month rehabilitation. <h3>Conclusions</h3> 6-month rehabilitation increases compliance to non-drug therapies, improves functional ability, motion activity and quality of life, reduces diseases activity in patients with early RA. The main reason for interruption of the rehabilitation is a low adherence to non-drug treatments, primarily – to home-based exercises. <h3>References</h3> Forestier R, et al. Joint Bone Spine 2009;76(6):691–8. Hurkmans EJ, et al. Rheumatology (Oxford) 2011;50(10):1879–88. <h3>Disclosure of Interest</h3> None Declared
1142 PEGIFNa-2A PLUS RIBAVIRIN SHOWS HIGHER SVR RATE COMPARE WITH PEGIFNa-2B PLUS RIBAVIRIN IN ELDERLY PATIENTS WITH CHRONIC HEPATITIS C SPECIALLY IN IL-28B MAJOR ALLELE
Authors: S. Miyase, Y. Morishita, K. Haraoka, Y. Ouchida, S. Fujiyama
Journal: Journal of Hepatology (2012)
Discrepancy Between Tc-99m HMDP Bone Scan and F-18 FDG Positron Emission Tomographic Images in a Patient with Small Cell Lung Cancer
Authors: KAZUKI FUKUCHI, MASATO YAMAGUCHI, KOHEI HAYASHIDA, YOSHIO ISHIDA
Journal: Clinical Nuclear Medicine (2003)

FUKUCHI, KAZUKI M.D.; YAMAGUCHI, MASATO M.D.; HAYASHIDA, KOHEI M.D.; ISHIDA, YOSHIO M.D. Author Information
Mast cells in asthma: biomarker and therapeutic target
Authors: Laurent L. Reber, John V. Fahy
Journal: European Respiratory Journal (2016)

The heterogeneity of asthma phenotypes represents a challenge for adequate assessment and treatment of the disease [1]. The molecular analysis of highly characterised cohorts of asthma patients should help to identify biomarkers of asthma subtypes, which might lead to more efficient and personalised therapies for asthma [1, 2]. So far, asthma has been mainly divided into two subtypes: T-helper cell type 2 (Th2)-high asthma, which comprises patients with airway and systemic eosinophilia who are responsive to glucocorticoids; and Th2-low asthma, which comprises patients without airway or systemic eosinophilia who are not responsive to glucocorticoids [3]. Besides eosinophilia, patients with Th2-high asthma have other signs of airway type 2 inflammation, including increased numbers of airway mast cells [4]. Mast cell numbers or activity levels could help identify asthma subtypes and be relevant for treatment effectiveness <http://ow.ly/Xmanp>
Abstract 3355: Identification of unique tumoricidal genes in rat umbilical cord matrix stem cells
Authors: Lakshmi D. Uppalapati, Naomi Ohta, Yongqing Zhang, Marla Pyle, Kevin G. Becker, Deryl L. Troyer, Masaaki Tamura
Journal: Cancer Research (2011)

Abstract Umbilical cord matrix stem cells (UCMSC) represent a promising source of therapeutics for various diseases including cancer. We have shown that naïve rat UCMSC significantly attenuate Fisher 344 rat-derived mammary adenocarcinoma (Mat B III) cell proliferation both in vivo and in vitro. To study the underlying mechanisms and genes involved in the Mat B III growth attenuation, we investigated gene expression profiles of naive rat UCMSC alone co-cultured with Mat BIII cells by cDNA microarray analysis. Total RNA was extracted from the naïve rat UCMSC alone and those co-cultured with Mat B III in transwell culture dishes. The comparison of gene expression profiles between untreated and co-cultured rat UCMSC identified five up-regulated (Follistatin (FST), Sulfatase1 (SULF-1), Glucose phosphate isomerase (GPI), HtrA serine peptidase (HTRA1), and Adipocyte differentiation-related protein (ADRP)) and two down-regulated (Transforming growth factor, beta-induced (TGFBI), Podoplanin (PDPN)) candidate genes based upon the following screening criteria: 1) candidate gene expression should show at least a 1.5 fold change in rat UCMSC co-cultured with Mat B III cells; 2) candidate genes encode secretory proteins; and 3) candidate genes encode cell growth-related proteins. Following confirmation of gene expression by real time-PCR, ADRP, SULF-1 and GPI were selected for further analysis. Addition of specific neutralizing antibodies against these three gene products individually or all together in the co-culture of Mat B III cells and 1/20 cell number of rat UCMSC significantly increased [3H] thymidine uptake in the Mat B III cells implying that these gene products are functionally produced under the co-cultured condition and attenuate cell growth. Immunoprecipitation followed by Western Blot analysis demonstrated that these proteins are indeed secreted into the culture medium. We are investigating the siRNA-dependent down regulation of these genes in rat UCMSC to confirm their tumor suppressor function. These results suggest that ADRP, SULF-1 and GPI act as tumor suppressor genes and these genes might be involved in rat UCMSC-dependent growth attenuation of rat mammary tumor. This work was supported by the Kansas State University (KSU) Terry C. Johnson Center for Basic Cancer Research, KSU College of Veterinary Medicine Dean's Fund, NIH P20 RR017686, p20RR1556, R21CA135599, Kansas Bioscience Authority research fund and by the Intramural Research Program of the NIH, National Institute on Aging. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3355. doi:10.1158/1538-7445.AM2011-3355
Hepatitis B and Hepatitis C in Emergency Department Patients
Authors: Gabor D. Kelen, Gary B. Green, Robert H. Purcell, Daniel W. Chan, Bahjat F. Qaqish, Keith T. Sivertson, Thomas C. Quinn
Journal: New England Journal of Medicine (1992)

Infections with hepatitis B virus (HBV), hepatitis C virus (HCV), and the human immunodeficiency virus type 1 (HIV-1) are common in inner-city populations, but their frequency and interrelations are not well established.
Hypocalcemia in the Presence of Osteoblastic Metastases
Authors: Marvin A. Sackner, Alfred P. Spivack, Lucy J. Balian
Journal: New England Journal of Medicine (1960)

A HITHERTO infrequently recognized abnormality in patients with osteoblastic metastases is the occurrence of hypocalcemia. It has usually been held that calcium levels are normal in this situation.1 However, Aegerter and Kirkpatrick2 state that the excess osteoid tissue present in these cases may take up sufficient calcium to keep the serum calcium at lower than normal levels. They suggest that rarely "dangerously low calcium levels" may be induced by this mechanism. It is the purpose of this report to describe a patient with extensive osteoblastic metastases, resulting from adenocarcinoma of the lung, who had persistent hypocalcemia.3 , 4 Case ReportW.S., a . . .
DPP-4 INHIBITOR AND ESTROGEN, BUT NOT METFORMIN, EXERT CARDIOPROTECTION VIA ATTENUATING CARDIAC MITOCHONDRIAL DYSFUNCTION IN OBESE-INSULIN RESISTANT AND ESTROGEN-DEPRIVED RATS
Authors: Sivaporn Sivasinprasasn, Piangkwan Sa-nguanmoo, Nattayaporn Apaijai, Wanpitak Pongkan, Wasana Pratchayasakul, Siriporn Chattipakorn, Nipon Chattipakorn
Journal: Journal of the American College of Cardiology (2015)
THU0306 Staying Healthy from Fibromyalgia is Ongoing Hard Work – Interviews of Women with Prior Fibromyalgia
Authors: H.E. Grape, K.N. Solbrække, M. Kirkevold, A.M. Mengshoel
Journal: Annals of the Rheumatic Diseases (2014)

Background Fibromyalgia syndrome (FMS) is a chronic musculoskeletal pain condition without any known curative treatment. Although studies have reported that some patients can become healthy again, little is known about what they tell about their lives after having recovered from FMS. Objectives What do women say about their everyday lives in the past having FMS and presently being healthy again? Methods Eight Norwegian women previously fulfilling the ACR-1990 criteria, but who now do not have FMS any more were interviewed about their experiences when ill and presently being healthy again. The study had a narrative approach with a thematic interview guide following a time line; everyday-life before, during and after FMS. The analysis was guided by understanding a narrative as a sequence of events with a beginning, middle and an end whereas the meaning of the story, the plot, weaves together the events into a whole, and a thematic, narrative analysis was conducted. Results The informants lived in rural and urban areas in different parts of Norway. Their age varied from 34 to 59 years. They differed in social and professional backgrounds and educational levels. All were employed, three of them part-time. The narratives about the past as ill was a story about “a struggling for survival” which constitutes a great effort invested in maintaining everyday life, as well as a struggling to understand what was wrong with them and obtain recognition for the reality of their affliction. Although everyday life presently has been restored and reassumed its content and meaning, the narratives about here and now describes how the women invest a considerable effort in remaining healthy. They are avoiding becoming ill again by exercises, diets and relaxation, and by watching their bodies for symptoms so they can take necessary preventive precautions. The narratives also describe how they have established daily routines and regimens for themselves to promote their health. Conclusions Remaining healthy from FMS requires ongoing hard bodily work. The plot linking the narratives about past as ill and present as healthy is a presentation of hard working women. Although FMS has retreated, it is there in the background and a strong reminder of something they do not wish to have back. Disclosure of Interest : None declared DOI 10.1136/annrheumdis-2014-eular.4386